Shen Yan, Ma Hai-Fen, Yang Yan-Li, Guan Jian-Long
Rheumatology and Immunology Department.
Medical Imaging Department, Huadong Hospital, Fudan University, Shanghai 200040, PR China.
Medicine (Baltimore). 2019 Oct;98(43):e17652. doi: 10.1097/MD.0000000000017652.
Intestinal Behçet's disease (BD) is characterized by intestinal ulcerations and gastrointestinal symptoms. Ulcerative intestinal tuberculosis (TB) is usually with dyspepsia, abdominal pain, vomiting, and weight loss. The 2 diseases exhibit similar clinical manifestations, but the most critical aspects of their clinical courses and required treatments are not at all similar.
We present a case in which a patient with intestinal Behçet's disease developed a de novo ulcerative intestinal TB infection after the start of anti-tumor necrosis factor-α treatment. This was despite histopathologic examination without caseous necrosis granuloma and negative for acid-fast staining and latent TB screen.
Intestinal Behçet's disease and intestinal TB.
The patient was treated with quadruple antituberculous chemotherapy, comprising rifapentine, isoniazid, ethambutol, and pyrazinamide.
At follow-up about 3 months, the therapy of oral antituberculous drugs and thalidomide was continued and the patient's condition had stabilized.
This case illustrates the importance of closely monitoring patients who are on infliximab for possible onset of TB, even without abdominal symptoms, and with negative screening results for latent TB.
肠道白塞病(BD)的特征是肠道溃疡和胃肠道症状。溃疡性肠结核(TB)通常伴有消化不良、腹痛、呕吐和体重减轻。这两种疾病表现出相似的临床表现,但它们临床病程的最关键方面和所需治疗方法却完全不同。
我们报告一例肠道白塞病患者在开始抗肿瘤坏死因子-α治疗后新发溃疡性肠结核感染的病例。尽管组织病理学检查未发现干酪样坏死肉芽肿,抗酸染色阴性且潜伏性结核筛查阴性。
肠道白塞病和肠结核。
患者接受了包含利福喷丁、异烟肼、乙胺丁醇和吡嗪酰胺的四联抗结核化疗。
在约3个月的随访中,继续口服抗结核药物和沙利度胺治疗,患者病情已稳定。
该病例说明了即使没有腹部症状且潜伏性结核筛查结果为阴性,对接受英夫利昔单抗治疗的患者密切监测是否可能发生结核病的重要性。